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County Health Department for further
testing and speciation. It was first test-
ed with a fluorescein-conjugated anti-
body for Neisseria gonorrhoeae;
results were negative. A RapID NH
panel (Remel, Lenexa, KS, USA) was
performed that identified the isolate
as M. osloensis with a 99.7% proba-
bility. Ideally, the isolate would have
undergone more comprehensive
genotypic and phenotypic characteri-
zation. However, as a presumed
Neisseria species, it was subjected to
the usual testing protocol at the health
department. Chlamydial culture was
performed by using buffalo green
monkey kidney cells (Viromed,
Minnetonka, MN, USA) grown under
standard conditions. No viral inclu-
sions were seen, and the culture did
not react with chlamydial antibodies
(Trinity Biotech, Bray, Ireland).
Because the child responded rapidly
to antimicrobial drug treatment, no
further workup of the bacterial isolate
was considered. The child was
healthy 3 days later and was dis-
charged to his home with topical
erythromycin and instructions to his
parents to follow up with his primary
care physician. 
Neonatal ophthalmia is a potential-
ly serious, sight-threatening infection
that may be caused by sexually trans-
mitted pathogens. Accordingly, this
clinical presentation warrants prompt
diagnosis and appropriate therapy. At
the same time, suspicion of a sexually
transmitted disease causes immense
social turmoil. Specific bacterial cul-
tures are essential for precise microbi-
ologic diagnosis and treatment. 
Cultures of conjunctival speci-
mens from our patient grew M.
osloensis. Clinically, this patient’s
infection was indistinguishable from
other causes of neonatal ophthalmia.
The differential diagnosis includes
other agents such as N. gonorrhoeae,
Chlamydia trachomatis,  M. catarr-
halis, Staphylococcus aureus, Haemo-
philus influenzae, and Streptococcus
pneumoniae. Rarely, gram-negative
enteric organisms may be implicated
(9). Viruses, such as adenovirus or
herpesvirus, are also a potential cause
but were unlikely in this case.
Finally, social issues must be con-
sidered. When an infant is seen with
neonatal ophthalmia, a physician will
often presume it to be gonococcal or
chlamydial and assume the mother is
positive for these infections. Recog-
nizing that Moraxella species, includ-
ing  M. osloensis, may produce an
identical clinical picture should limit
presumptions regarding sexually
transmitted diseases until a precise
microbiologic diagnosis is made. 
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To the Editor: African tick-bite
fever (ATBF) is caused by Rickettsia
africae and remains the most common
tickborne rickettsiosis in sub-Saharan
Africa (1,2). We describe an outbreak
of ATBF in 10 of 34 French tourists
on their return from South Africa in
March 2005. Fever, skin rash, and
multiple eschars on the legs devel-
oped in the index case-patient (patient
9, Table). After informed consent was
obtained, the tourists completed a
questionnaire for epidemiologic and
clinical data. Acute- and convales-
cent-phase serum samples were col-
lected when possible for serologic
analysis performed at the Unité des
Rickettsies. The samples were tested
against a panel of antigens including
R. typhi, Francisella tularensis,
Coxiella burnetii, Borrelia burgdor-
feri, Anaplasma phagocytophylum, R.
felis, R. helvetica, R. conorii subsp.
conorii strain Malish, R. africae, R.
sibirica mongolotimonae, R. massili-
ae, and  R. slovaca, as previously
described (3). A case of symptomatic
confirmed ATBF was defined as
clinical illness and positive serologic
results against R. africae, whereas a
case of probable ATBF was defined as
typical clinical symptoms withoutLETTERS
definite serologic evidence of R.
africae infection.
Of the 34 travelers, 30 completed
the questionnaire and 20 consented to
give at least 1 serum sample. After
their return to France, symptoms com-
patible clinically with ATBF devel-
oped in 10 of the travelers (Table) and
9 had positive serologic results and/or
a seroconversion for spotted fever
group–rickettsia, including R. africae
(Table). The median time from illness
onset to serum testing was 19 days.
Thus, 9 of the travelers had probable
and 1 had possible (no serum was
available) ATBF. Including both prob-
able and possible cases, the illness
rate for the whole group was 33.3%
(10/30). None of the travelers report-
ed a history of tick bite. The delay
between probable exposure and onset
of symptoms was 3–10 days (mean ±
standard deviation 6.1 ± 1.9 days).
Multiple eschars on the legs or arms
were seen in 7 (70%) of 10 patients.
Eight patients received doxycycline
(200 mg per day) for a mean of 10.8 ±
5.9 days (range 5–20), 1 patient
received pristinamycin for 8 days, and
1 patient received no treatment. All
patients recovered fully without
sequela; however, 6 patients reported
convalescent-phase asthenia and 1
reported chronic insomnia, which had
not occurred previously, for 2 months
after the illness. Among the 10
remaining travelers, for whom a
serum sample was available, with no
clinical evidence of ATBF, 5 were
positive for R. africae with only
immunoglobulin M (IgM) at a titer of
1:32 in 4 cases and IgG at 1:128 with
IgM at 1:32 in 1 case (an acute-phase
serum from this patient showed IgG at
1:32 and IgM at 1:32). The 5 other
travelers had negative serologic
results. Results of serologic testing for
other bacteria were negative for all
travelers. Twenty-four travelers
(80%), including the 10 symptomatic
patients, reported using topical insect
repellent daily.
Most cases of ATBF are reported
in clusters of travelers exposed to
ticks during game hunting or safaris,
as described here (1,3–5). The esti-
mated incidence of African tick-bite
fever in safari travelers is 4%–5.3%
(4) but higher incidence may be
reported as emphasized in our study.
In our study, epidemiologic and clini-
cal data for the 10 symptomatic
patients were obtained in accordance
with current knowledge of ATBF (2). 
Skin biopsy samples remain the
best tool to isolate or detect R. africae
(2,6). However, specific serologic
tests, especially immunofluorescence
assays, remain the most widely used
microbiologic test worldwide (7). No
commercially available test for ATBF
exists but due to extensive cross-reac-
tions between spotted fever group
rickettsiosis, commercial kits based on
the detection of R. conorii antibodies
can be used for the diagnosis of ATBF.
Most tourists reported using topical
insect repellents without any efficacy.
Applying repellents to exposed skin
provides little protection against ticks
because they can crawl underneath
clothing and bite untreated portions of
the body (8). Thus, treating clothing
with synthetic pyrethroid insecticide is
recommended to complement the top-
ical repellant (8). 
In conclusion, our study empha-
sizes the importance of ATBF as a
common cause of flulike illness in
travelers returning from South Africa,
but with a higher rate than malaria,
typhoid fever, or other tropical fevers.
The most important clinical clues are
the presence of clustered cases with
multiple inoculation eschars. Health-
care professionals who are providing
advice should inform persons travel-
ing to endemic areas of Africa of the
risk of contracting ATBF and the
importance of protecting themselves
against tick bites. Chemoprophylaxis
with doxycycline is not recommended,
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however, this recommendation may be
evaluated in future clinical trials.
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